Improving the Drug Development Pipeline for Mycobacteria: Modelling Antibiotic Exposure in the Hollow Fibre Infection Model
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improving the Drug Development Pipeline for Mycobacteria: Modelling Antibiotic Exposure in the Hollow Fibre Infection Model
Authors
Keywords
-
Journal
Antibiotics-Basel
Volume 10, Issue 12, Pages 1515
Publisher
MDPI AG
Online
2021-12-10
DOI
10.3390/antibiotics10121515
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease
- (2021) Kiyoharu Fukushima et al. Scientific Reports
- Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
- (2021) Shashikant Srivastava et al. Frontiers in Pharmacology
- Vancomycin’s potency against Mycobacterium tuberculosis in the hollow fiber system model
- (2021) Shashikant Srivastava et al. Journal of Global Antimicrobial Resistance
- Higher dosing of rifamycins does not increase activity against M. tuberculosis in the hollow fibre infection model.
- (2021) E.D. Pieterman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration
- (2021) Tawanda Gumbo et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
- (2021) C. D. Tweed et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics
- (2021) Mike Marvin Ruth et al. CLINICAL MICROBIOLOGY AND INFECTION
- Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting
- (2021) Zahra Sadouki et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
- (2020) Francesca Conradie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Pulmonary Multidrug-Resistant Tuberculosis Patients
- (2020) Suresh Mallikaarjun et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Why big pharma has abandoned antibiotics
- (2020) Benjamin Plackett NATURE
- Clinical relevance of non-tuberculous mycobacteria isolated from respiratory specimens: seven year experience in a UK hospital
- (2019) H. F. Schiff et al. Scientific Reports
- Once-a-week tigecycline for the treatment of drug-resistant TB
- (2019) Devyani Deshpande et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans
- (2019) Jürgen B. Bulitta et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models
- (2019) Mike M Ruth et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In Vitro Granuloma Models of Tuberculosis: Potential and Challenges
- (2019) Paul Elkington et al. JOURNAL OF INFECTIOUS DISEASES
- Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?
- (2019) Frank Kloprogge et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics
- (2019) Shashikant Srivastava et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection
- (2019) Frank Kloprogge et al. Scientific Reports
- NTM drug discovery: status, gaps and the way forward
- (2018) Mu-Lu Wu et al. DRUG DISCOVERY TODAY
- The Activity of Moxifloxacin against Acid-Phase and Non-Replicative Persister Phenotype Phase Mycobacterium tuberculosis in a Hollow Fiber Infection Model
- (2018) Arnold Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- The present state of the tuberculosis drug development pipeline
- (2018) M Daben J Libardo et al. CURRENT OPINION IN PHARMACOLOGY
- Dose Optimization of Moxifloxacin and Linezolid Against Tuberculosis Using Mathematical Modeling and Simulation
- (2018) M. Tobias Heinrichs et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant Tuberculosis
- (2018) Devyani Deshpande et al. JOURNAL OF INFECTIOUS DISEASES
- Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance
- (2017) Shashikant Srivastava et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent
- (2017) Devyani Deshpande et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A ‘shock and awe’ thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium–intracellulare complex disease
- (2017) Shashikant Srivastava et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Linezolid as treatment for pulmonary Mycobacterium avium disease
- (2017) Devyani Deshpande et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease
- (2017) Devyani Deshpande et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting
- (2017) Devyani Deshpande et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis
- (2017) Devyani Deshpande et al. Science Advances
- Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis
- (2016) Shashikant Srivastava et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease
- (2016) Beatriz E. Ferro et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Flow Cytometry Method for Rapidly Assessing Mycobacterium tuberculosis Responses to Antibiotics with Different Modes of Action
- (2016) Charlotte Louise Hendon-Dunn et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs
- (2016) Arundhati Maitra et al. BRITISH MEDICAL BULLETIN
- A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way
- (2016) Devyani Deshpande et al. CLINICAL INFECTIOUS DISEASES
- Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps
- (2016) Devyani Deshpande et al. CLINICAL INFECTIOUS DISEASES
- Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo
- (2016) Devyani Deshpande et al. CLINICAL INFECTIOUS DISEASES
- Serial image analysis of Mycobacterium tuberculosis colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB
- (2016) David A. Barr et al. TUBERCULOSIS
- Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool: Figure 1.
- (2015) Klaus Romero et al. CLINICAL INFECTIOUS DISEASES
- Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes
- (2015) Tawanda Gumbo et al. CLINICAL INFECTIOUS DISEASES
- Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience
- (2015) Marco Cavaleri et al. CLINICAL INFECTIOUS DISEASES
- Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm
- (2015) Tawanda Gumbo et al. CLINICAL INFECTIOUS DISEASES
- Repurposing—a ray of hope in tackling extensively drug resistance in tuberculosis
- (2015) Arundhati Maitra et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Transcriptional Adaptation of Drug-tolerantMycobacterium tuberculosisDuring Treatment of Human Tuberculosis
- (2015) Nicholas D. Walter et al. JOURNAL OF INFECTIOUS DISEASES
- Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy
- (2015) Ashley N. Brown et al. mBio
- Bedaquiline: a review of human pharmacokinetics and drug-drug interactions
- (2014) R. P. G. van Heeswijk et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis
- (2014) Corinne S. Merle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
- (2014) Stephen H. Gillespie et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
- (2014) Amina Jindani et al. NEW ENGLAND JOURNAL OF MEDICINE
- PK/PD models in antibacterial development
- (2013) Tony Velkov et al. CURRENT OPINION IN MICROBIOLOGY
- Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence
- (2013) Jakko van Ingen et al. Expert Review of Anti-Infective Therapy
- Efflux as a mechanism for drug resistance inMycobacterium tuberculosis: Table 1
- (2011) Pedro Eduardo Almeida da Silva et al. FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY
- Molecular Bacterial Load Assay, a Culture-Free Biomarker for Rapid and Accurate Quantification of Sputum Mycobacterium tuberculosis Bacillary Load during Treatment
- (2011) Isobella Honeyborne et al. JOURNAL OF CLINICAL MICROBIOLOGY
- In vitro pharmacodynamic models to determine the effect of antibacterial drugs
- (2009) J. Gloede et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now